Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era

•Primary sites affected efficacy of chimeric antigen receptor T cell (CART) therapy.•Extranodal patients had inferior prognosis than nodal patients with CART therapy.•Autologous hematopoietic stem cell transplantation (ASCT) improved the prognosis.•ASCT combined with CART therapy presented superior outcomes than CART alone.